BioVersys AG (XSWX:BIOV) Other Stockholders Equity: CHF-0.51 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIOV BioVersys AG XSWX:BIOV
4 GF Score
Price CHF27.50
View Full Analysis

What is BioVersys AG Other Stockholders Equity?

BioVersys AG XSWX:BIOV +3.77% 4 Other Stockholders Equity is CHF-0.51 Mil as of Dec. 2025. GuruFocus rates XSWX:BIOV with a GF Score™ of 4/100.

BioVersys AG's Other Stockholders Equity for the quarter that ended in Dec. 2025 was CHF-0.51 Mil.

BioVersys AG's quarterly Other Stockholders Equity declined from Dec. 2024 (CHF-0.07 Mil) to Jun. 2025 (CHF-0.62 Mil) but then increased from Jun. 2025 (CHF-0.62 Mil) to Dec. 2025 (CHF-0.51 Mil).

BioVersys AG's annual Other Stockholders Equity increased from . 20 (CHF0.00 Mil) to Dec. 2024 (CHF-0.07 Mil) but then declined from Dec. 2024 (CHF-0.07 Mil) to Dec. 2025 (CHF-0.51 Mil).

BioVersys AG Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for BioVersys AG's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioVersys AG Other Stockholders Equity Chart

BioVersys AG Annual Data
Trend Dec24 Dec25
Other Stockholders Equity
-0.07 -0.51

BioVersys AG Semi-Annual Data
Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity 0.00 -0.07 -0.62 -0.51
XSWX:BIOV
4GF Score
BioVersys AG XSWX:BIOV
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioVersys AG Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of CHF-0.51 Mil mean?
BioVersys AG (XSWX:BIOV) has a Other Stockholders Equity of CHF-0.51 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on BioVersys AG and its competitors.
Is BioVersys AG's Other Stockholders Equity too high?
BioVersys AG's current Other Stockholders Equity is CHF-0.51 Mil. Overall, BioVersys AG has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BioVersys AG's Other Stockholders Equity compare to VRTX and REGN?
BioVersys AG's Other Stockholders Equity of CHF-0.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on BioVersys AG and its competitors. BioVersys AG's current Other Stockholders Equity is CHF-0.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioVersys AG stock overvalued right now?
BioVersys AG (XSWX:BIOV) has a current Other Stockholders Equity of CHF-0.51 Mil. The current Other Stockholders Equity is CHF-0.51 Mil. BioVersys AG's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For BioVersys AG (XSWX:BIOV), the current Other Stockholders Equity is CHF-0.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioVersys AG Business Description

Other Exchanges BIOVz:UKW33:Germany
Address c/o Technologiepark, Hochbergerstrasse 60c, Basel, CHE, CH-4057
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
4GF Score

Get the complete analysis for XSWX:BIOV

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF27.50
Price